Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Clearmind

Why Is Clearmind Stock Down Today?

Shares of Clearmind Medicine Inc. (NASDAQ:CMND) are falling Friday after the clinical-stage biotech company shared a key update about its stock listing.

Benzinga · Nov 7, 2025

Clearmind Medicine Files US Patent Application For Dyskinesia Treatment

Clearmind Medicine Inc files a provisional patent application for the treatment of Dyskinesia, Strengthening IP Portfolio

Zenger · Aug 2, 2023

Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know

Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC Pink: CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd.

Benzinga · Aug 24, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction

SciSparc Ltd. (NASDAQ: SPRC) collaboration with Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) resulted in the filing of a provisional patent application related to treating cocaine addiction.

Benzinga · Jun 2, 2022

Patent For Psychedelic-Based Alcohol Substitute Approved In India, Produced By Clearmind Medicine

India's Office of the Controller-General of Patents, Designs and Trademarks granted approval for a new compound created by the biotech company Clearmind Medicine Inc. (OTC Pink: CMNDF).

Benzinga · Jun 1, 2022

High Hopes For Alcohol Use Disorder Treatment: Clearmind's Successful Pre-IND Meeting With The FDA

The meeting, which took place on May 18 between the psychedelic pharmaceutical biotech company Clearmind Medicine Inc. (CMNDF) and the US Food and Drug Administration marks the completion the pre-IND New Drug Application stage.

Benzinga · May 26, 2022

Psychedelic Treatment For Alcoholism? Clearmind Medicine And SciSparc Collaboration Yields Positive Results

Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, revealed positive safety profile results from its joint pre-clinical trial with SciSparc Ltd.

Benzinga · May 24, 2022

Read news from The Economist, FT, and more,
with one subscription

Clearmind: Positive Preclinical Evidence For Flagship Psychedelic Molecule, Looks To Human Trials Before Year End

Psychedelics biotech company Clearmind Medicine Inc.

Benzinga · May 19, 2022

Has Clearmind Developed A Psychedelics-Based Drug That Can Treat Alcoholism? The FDA Is Interested

On Wednesday, May 18, Clearmind Medicine Inc. (OTC Pink: CMNDF) will meet with the Center for Drug Evaluation and Research (CDER), a department within the FDA.

Benzinga · May 13, 2022

Alcoholism & Psychedelics: Clearmind Trials Reveal Certain Psychedelics Help Reduce Alcohol Consumption In Mice

The first trial examined the effect of CMND-100 in several doses as a monotherapy. The second, done in collaboration with SciSparc Ltd. (NASDAQ:SPRC), examined the synergetic effect of combining lower concentrations of CMND-100 with SciSparc's CannAmide (proprietary formulation of Palmitoylethanolamide or PEA).

Benzinga · Mar 17, 2022

Coverage From

Organisations

US Food and Drug Administration

Clearmind Medicine Inc

10 stories

SciSparc Ltd

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.